Comparative Pharmacology
Head-to-head clinical analysis: CUTIVATE versus DEXAMETHASONE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUTIVATE versus DEXAMETHASONE INTENSOL.
CUTIVATE vs DEXAMETHASONE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; modulates gene expression to inhibit inflammatory mediators, vasoconstriction, and immunosuppression.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects via inhibition of phospholipase A2, reduction of prostaglandins and leukotrienes, and modulation of gene transcription.
Apply a thin layer to affected skin areas once or twice daily. Therapy should be discontinued when control is achieved; if no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
0.75-9 mg/day orally in divided doses every 6-12 hours; for anti-inflammatory/immunosuppressive effects, initial dose 0.75-9 mg/day; for cerebral edema, 10 mg IV then 4 mg IM/IV every 6 hours.
None Documented
None Documented
2-4 hours (terminal elimination half-life); short half-life supports twice-daily dosing for maintenance of clinical effect.
Terminal elimination half-life: 36-54 hours (adults); clinically, biological half-life (duration of HPA axis suppression) is longer (24-72 hours).
Primarily hepatic metabolism; metabolites are excreted renally and fecally. Unchanged drug is negligible in urine. Route: renal (~60% as metabolites), fecal (~40% as metabolites).
Renal (approximately 65-80% as metabolites, <10% as unchanged drug); biliary/fecal (minor).
Category C
Category D/X
Corticosteroid
Corticosteroid